Repeat Dose Safety Study for Compound to Treat Anemia

Status Completed

Clinical Trial Summary

The purpose of this study is to characterize the safety and tolerability of repeat doses of compound 1278863A in healthy subjects.

Clinical Trial Description

Compound 1278863A is a novel small molecule agent, which stimulates erythropoiesis through inhibition of hypoxia-inducible factor (HIF)-prolyl hydroxylases (EGLNs). This compound is being developed for the treatment of anemia. Compound 111427 was the first administration of compound 1278863A to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses up to 300 mg in healthy adult subjects. This study, PHI112842, will be the first administration of compound 1278863A to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of repeat oral doses up to 300 mg for 14 days in healthy adult subjects. At least 6 subjects will complete each cohort. Multiple blood samples for pharmacokinetic analyses will be obtained post-dose in each cohort. Safety will be assessed by measurement of vital signs, cardiac monitoring, collection of adverse event assessments and laboratory safety tests. Blood samples will be collected for pharmacodynamic analyses. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00840320
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 1
Start date	March 13, 2009
Completion date	September 2, 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02369354` - Transplant Social Worker Support for Live Kidney Donation in African Americans	N/A
Not yet recruiting	`NCT02225782` - Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function	Phase 4
Completed	`NCT00499187` - Fanconi Syndrome Due to ARVs in HIV-Infected Persons	Phase 4
Completed	`NCT00379899` - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis	Phase 4
Withdrawn	`NCT00585429` - Evaluation of Kidney Disease in Liver Transplant Recipients	N/A
Completed	`NCT00183248` - Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients	Phase 1/Phase 2
Completed	`NCT00001835` - Oxaliplatin in Cancer Patients With Impaired Kidney Function	Phase 1
Completed	`NCT01331941` - A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function	Phase 1
Terminated	`NCT00436748` - Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease	Phase 3
Completed	`NCT01467466` - Prevention of Serious Adverse Events Following Angiography	Phase 3
Completed	`NCT01235936` - Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia	Phase 2
Completed	`NCT01974999` - A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study
Completed	`NCT01947829` - Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)	N/A
Recruiting	`NCT01240564` - The Nephrotic Syndrome Study Network (NEPTUNE)	N/A
Active, not recruiting	`NCT01228903` - Uric Acid and the Endothelium is CKD	N/A
Completed	`NCT00734357` - Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients	N/A
Completed	`NCT00781417` - Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease	N/A
Completed	`NCT00185159` - Olmesartan Medoxomil in Diabetes Mellitus	Phase 3
Completed	`NCT00094484` - Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis	Phase 3
Completed	`NCT00093977` - Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease	Phase 3